Exagen (XGN) is a speculative buy with promising growth in diagnostics, new lupus/RA tests, and potential positive EBITDA by ...

In addition to pharmaceuticals, Trump has also called for Section 232 investigations of semiconductors and critical minerals.

In a market where every technology investment must be justified with hard data, QKS Group is raising the bar with its newly ...

The story of your company's evolution may seem uninspiring to you, but it can play an important role in building trust a ...